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OBJECTIVES In this study, we assess the value of sirolimus eluting stent (SES) implantation in patients
with complex in-stent restenosis (ISR).
BACKGROUND The treatment of ISR remains a therapeutic challenge, since many pharmacological and
mechanical approaches have shown disappointing results. The SESs have been reported to be
effective in de-novo coronary lesions.
METHODS Sixteen patients with severe, recurrent ISR in a native coronary artery (average lesion length
18.4 mm) and objective evidence of ischemia were included. They received one or more
18 mm Bx VELOCITY SESs (Cordis Waterloo, Belgium). Quantitative angiographic and
three-dimensional intravascular ultrasound (IVUS) follow-up was performed at four months,
and clinical follow-up at nine months.
RESULTS The SES implantation (n  26) was successful in all 16 patients. Four patients had recurrent
restenosis following brachytherapy, and three patients had totally occluded vessels preproce-
dure. At four months follow-up, one patient had died and three patients had angiographic
evidence of restenosis (one in-stent and two in-lesion). In-stent late lumen loss averaged
0.21 mm and the volume obstruction of the stent by IVUS was 1.1%. At nine months clinical
follow-up, three patients had experienced four major adverse cardiac events (two deaths and
one acute myocardial infarction necessitating repeat target vessel angioplasty).
CONCLUSIONS The SES implantation in patients with severe ISR lesions effectively prevents neointima
formation and recurrent restenosis at four months angiographic follow-up. (J Am Coll
Cardiol 2003;41:184–9) © 2003 by the American College of Cardiology Foundation
Coronary stent implantation is the main therapeutic ap-
proach to coronary stenosis in interventional cardiology.
Consequently the most common form of restenosis today is
in-stent restenosis (ISR). The treatment of ISR remains a
therapeutic challenge, as all pharmacological and mechani-
cal treatment modalities have shown disappointing results.
The recurrence of ISR was reported to be in the range of
20% to 40% (1,2).
Intracoronary radiation is the only therapy for ISR proven
to be effective in randomized clinical trials (3,4). However,
restenosis is not eliminated. The wide spread use of brachy-
therapy is limited by logistic requirements and potential side
effects (5,6).
Attention is now focusing on the concept of local
pharmacologic intervention by drug-eluting stents. Siroli-
mus has been shown to be effective in de-novo lesions with
a remarkable restenosis rate of 0% in some studies (7,8).
These findings provoked considerable enthusiasm (9), but
also profound skepticism (10). The major criticism focused
on the lack of data in complex lesions and on the lack of
long-term data.
The aim of our study was to evaluate the effectiveness of
sirolimus eluting stents (SESs) in preventing neointimal
formation in patients with severe ISR.
METHODS
Patient population. Patients with recurrent ISR in a native
coronary artery and objective evidence of ischemia were
included. The vessel size had to be2.5 mm and3.5 mm.
Between March and June 2001, 16 consecutive patients
were included. All patients signed a written informed
consent. The Medical Ethics Committee at our institution
had approved the study protocol.
ISR definition. In-stent restenosis was defined as 50%
diameter stenosis (DS) by quantitative coronary angiogra-
phy (QCA) within a previously (at least four months)
stented vessel segment. In-stent restenosis was classified as
focal (10 mm long), diffuse (10 mm long), proliferative
(10 mm long and extending outside the stent edges), or
totally occluded (11).
Procedure. All ISR lesions were predilated. Then, a SES
Bx VELOCITY (Cordis Waterloo, Belgium) was im-
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planted using conventional techniques. The stent was
loaded with 140 g sirolimus/cm2 metal surface area in a
slow release formulation (28 days drug release). All stents
were 18 mm long and 2.5 to 3.5 mm in diameter. Postdi-
latation was performed as required.
All patients received aspirin (325 mg/day, indefinitely)
and clopidogrel (300 mg loading dose immediately after
stent implantation followed by 75 mg/day for two to four
months at the discretion of the operator).
QCA and intravascular ultrasound (IVUS) analysis. Se-
rial coronary angiography was performed at baseline (before
and after intervention) and at four months follow-up.
In-stent and in-lesion (stent plus 5 mm proximal and 5 mm
distal to the stent) restenosis was defined as 50% DS at
follow-up.
The QCA analysis was performed by an independent
core laboratory (Brigham and Women’s Hospital, Boston,
Massachusetts).
Serial IVUS was performed using motorized pullback at a
constant speed of 0.5 mm/s postprocedure and at four
months follow-up. The quantitative ultrasound analyses
were performed by an independent core laboratory (Cardi-
alysis BV, Rotterdam, The Netherlands).
Statistical analysis. Continuous variables are expressed as
mean  standard deviation. Because of the small sample
size no statistical comparison was performed. Only the
IVUS data were expressed as mean and 95% confidence
interval.
RESULTS
Baseline characteristics. Sixteen patients were included in
the study. The patients’ demographics are summarized in
Table 1. Five patients presented with unstable angina and
four patients had diabetes mellitus. Four patients with
recurrent ISR after intracoronary beta-brachytherapy and
one heart transplant recipient with proliferative ISR were
included.
Procedural data. Lesion and procedural characteristics are
shown in Table 2. The average length of the restenotic
segment was 18.4  13.1 mm: three lesions were focal, five
diffuse, five proliferative, and three showed total occlusion
of the stent.
A total of 26 SESs were implanted. Nine patients
received a single stent, and six patients received two stents to
cover long lesions. In one patient with a totally occluded
vessel, five SESs were implanted. All patients were dis-
charged without complication one day after the procedure.
Angiographic outcome and three-dimensional IVUS
analysis. The QCA data are presented in Table 3 and the
IVUS data are shown in Table 4. Satisfactory angiographic
results were achieved in 15 out of 16 patients. Representa-
tive sequences of angiograms and IVUS from a single
patient are shown in Figure 1.
In one patient who received two SESs in an occluded
obtuse marginal branch of the circumflex artery, adequate
stent expansion could not be achieved despite the use of
high pressure (24 atm), noncompliant balloon inflation. The
final QCA revealed a residual stenosis of 34%. At follow-up,
this patient showed restenosis with silent target vessel
occlusion.
Two other patients showed 59% and 62% in-lesion DS,
respectively, at follow-up without evidence of cardiac isch-
emia. The first patient had received two SESs. Both IVUS
and angiographic analysis revealed a gap of 2.2 mm
between the two SESs. Neointimal hyperplasia (NIH)
occurred precisely at the bare segment between the two
Table 1. Baseline Clinical Characteristics
Variable n (%)
Patients 16
Male gender 12 (75)
Age, yrs 56.9  13.9
Unstable angina pectoris 5 (31)
Multivessel disease 11 (68.7)
Diabetes mellitus 4 (25)
Hypertension 9 (56.2)
Hyperlipidemia 8 (43.7)
Previous MI 9 (56.2)
Previous brachytherapy 4 (25)
Previous CABG 1 (6.2)
Previous heart transplantation 1 (6.2)
Values are n (%) or mean  SD.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction.
Table 2. Lesion and Procedural Characteristics
Treated vessels
Left anterior descending 6 (37.5)
Left circumflex 4 (25)
Right coronary artery 6 (37.5)
In-stent restenosis type
Focal 3 (18.7)
Diffuse intra-stent 5 (31.2)
Proliferative 5 (31.2)
Total occlusion 3 (18.7)
Lesion length, mm 18.4  13.1
Lesion length 10mm 13 (81.2)
Number of previous PCI per lesion 1.68  0.87
Previous implanted stent length (mm) 20.1  6.1
Number of SES per lesion 1.62  1.02
Implanted SES (mm) 28.5  18.0
Implanted SES diameter (mm) 3.01  0.38
Max. inflation pressure (atm) 16.1  3.58
Data are presented as numbers, (relative percentages), or mean  SD.
PCI  percutanenus coronary intervention; SES  sirolimus eluting stent.
Abbreviations and Acronyms
DS  diameter stenosis
ISR  in-stent restenosis
IVUS  intravascular ultrasound
NIH  neointimal hyperplasia
QCA  quantitative coronary angiography
SES  sirolimus eluting stent
TIMI  Thrombolysis In Myocardial Infarction
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stents (Fig. 2). A repeat intervention was not performed
because the patient was asymptomatic, intracoronary pres-
sure measurement showed a fractional flow reserve of 0.80,
and the stenosis was assessed as 50% DS by online QCA.
The second case was the heart transplanted recipient who
had a 62% DS proximal to the stent. The vessel, which had
Thrombolysis In Myocardial Infarction (TIMI) grade 1
flow prior to implantation of the SESs, had been extensively
ballooned during the procedure and the injured area was not
completely covered by SES. As the patient had no evidence
of ischemia by radionuclide scintigraphy, repeat revascular-
ization was not performed. All other patients showed only
minimal late lumen loss.
In one patient who had previously undergone brachyther-
apy and showed recurrent ISR associated with a “black hole”
(12) (echolucent tissue, rich in proteoglycans and poor in
mature collagen and elastin) prior to SES implantation,
IVUS showed reappearance of the “black hole” four months
after SES implantation without significant stenosis. The
eccentric, nonobstructive, echolucent luminal tissue was
situated in the proximal portion of the stent.
Nine months clinical outcome. The major adverse cardiac
events are summarized in Table 5. One patient with severe
three-vessel disease died suddenly 3.5 months after success-
ful implantation of two overlapping SESs in the right
coronary artery. Unfortunately, no clinical or autopsy infor-
mation is available.
The second patient, who had received five SESs, showed
no late lumen loss at five months follow-up, but developed
an inferior myocardial infarction seven months after the
index procedure. This event occurred after the follow-up
angiogram three weeks after discontinuing clopidogrel.
Angiography revealed a proximal total occlusion of the
artery. The patient was treated with thrombus aspiration.
Intravascular ultrasound after thrombectomy showed a well-
expanded stent without NIH.
Table 3. Quantitative Coronary Analysis by Core Laboratory
Parameters 15 Patients*
Pre-procedure
RD, mm 2.68  0.33
MLD, mm 0.59  0.50
DS, % 77.2  18.9
Lesion length, mm 18.4  13.1
Post-procedure
RD, mm 2.74  0.38
In-lesion MLD, mm 2.23  0.41
In-stent MLD, mm 2.58  0.37
In-lesion DS, % 18.4  10.0
In-stent DS, % 5.44  11.3
Follow-up
RD, mm 2.73  0.40
In-lesion MLD, mm 1.97  0.82
In-stent MLD, mm 2.36  0.80
In-lesion DS, % 26.9  27.0
In-stent DS, % 11.6  27.3
Restenosis
In-lesion (%) 2 (13.3)
In-stent (%) 1 (6.7)
Change in MLD
In-lesion late loss 0.26  0.67
In-stent late loss 0.21  0.62
In-lesion late loss index 0.14  0.38
In-stent late loss index 0.09  0.30
Data are presented as number relative percentages or mean value SD. *One patient,
who died 3.5 months after the procedure, was not included in this analysis.
DS  diameter stenosis; MLD  minimal luminal diameter; RD  reference
diameter.
Table 4. Volumetric Intravascular Ultrasound Measurements by Core Laboratory
N  11
Post-Procedure 4-Month Follow-Up
Mean (95% CI/95% CI) Mean (95% CI/95% CI)
Stent length (mm) 20.5  5.9 (16.5/24.4) 20.3  6.3 (16.1/24.5)
Stent volume (mm3) 159.7  57.3 (121.2/198.2) 158.6  69.3 (112.1/205.2)
Lumen volume (mm3) 159.7  57.3 (121.2/198.2) 157.1  69.9 (110.1/204.1)
NIH (mm3) NA 1.5  3.3 (0.71/3.73)
Volume obstruction (%) NA 1.1  2.6 (0.61/2.85)
CI  confidence interval; NIH  neointimal hyperplasia.
Figure 1. A chronically occluded left circumflex due to in-stent restenosis
(PRE) was treated with a sirolimus eluting stent (POST). Follow-up (FU)
angiography showed no restenosis; intravascular ultrasound (IVUS) revealed
no neointimal hyperplasia with the clear appearance of double stent struts.
* indicates the position of the IVUS catheter.
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Figure 2. (A) Angiograms: the long proliferative in-stent restonsis (ISR) (PRE) was treated with two sirolimus eluting stents (SESs) (POST). The
follow-up angiogram showed focal-repeat ISR (62% DS) in the gap (arrow), which was not covered by the SES. No neointimal hyperplasia (NIH) was
evident in the two SESs (A and C). (B) Intravascular ultrasound (IVUS): follow-up IVUS showed no NIH in the proximal (A) and distal (C) SES with
images of two layers of stent struts. Neointimal hyperplasia was noted in the gap region (B) where only one layer of (bare) stent struts can be seen. * indicates
the position of the IVUS catheter at the gap segment.
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The third patient, who had failed brachytherapy, had no
evidence of NIH at a four months follow-up IVUS, but died
due to congestive heart failure 9.5 months after the index
procedure. This 79-year-old man with left main coronary
artery disease and congestive heart failure had undergone
bypass surgery twice and had percutaneous coronary inter-
vention four times before the index procedure.
DISCUSSION
In this study, we describe the application of SESs in a subset
of patients presenting with extremely complex lesions and one
of the most challenging therapeutic problems today, which
is ISR. Notwithstanding the challenging population treated,
we found strikingly similar results in terms of suppression of
neointimal proliferation to that reported previously in
lower-risk patient populations (13). The acute procedural
and in-hospital outcome was uneventful. At a four months
angiographic follow-up, only one patient with prior total
occlusion showed repeat ISR due to silent total reocclusion
of the vessel. In the remaining patients, late lumen loss
averaged 0.08 mm and volume obstruction within the stent
was 1.1%. This is extremely low compared to other treat-
ment strategies, including brachytherapy. By contrast, con-
temporary studies report a restenosis rate of 45% for bare
stent–in-stent implantation with a late lumen loss of 1.36
mm (2). A registry of patients undergoing rotational
atherectomy followed by beta-radiation revealed a restenosis
rate of 10% with a late lumen loss of 0.37 mm (14).
Important clinical findings. Despite our relatively small
patient population, we witnessed some remarkable phenom-
ena. First, we observed NIH in a gap between two SESs and
at a site of injury that was not completely covered by the
SES. This case illustrates the therapeutic power of SESs,
since the patient serves as his own control (Fig. 2).
Second, we monitored the treatment of a patient with
severe transplant vasculopathy. The patient presented with a
small, diffusely diseased vessel and impaired flow (TIMI
grade 1) and received two sequential, overlapping 2.5 mm
diameter SESs at the site of ISR. The vessel segment
proximal to the stents was treated by balloon dilation. At
follow-up there was only minimal NIH within the SESs,
and angiographic restenosis occurred at the proximal adja-
cent vessel segment, outside the stents.
Third, we examined the treatment of patients after failed
brachytherapy. We treated four patients who had failed
brachytherapy, two of whom developed clinical events. The
third patient revealed a reappearance of the “black hole” at
follow-up IVUS; nonetheless, no significant stenosis was seen
at follow-up angiography. Brachytherapy failure patients were
responsible for one-third of all adverse events and represent a
particular challenge. These patients can have prolonged endo-
thelial dysfunction that can increase the risk of thrombosis;
there are no current data available on the combined effect of
radiation and cytostatic drug therapy in coronary arteries.
Late vessel occlusion occurred in two additional patients
who had not been treated with brachytherapy. One patient
with five drug-eluting stents experienced acute vessel closure
and developed myocardial infarction after follow-up angiog-
raphy and IVUS three weeks after discontinuing clopi-
dogrel. Intravascular ultrasound performed at the time of
the acute myocardial infarction showed no evidence of
NIH within the stents and thrombus formation as the
cause for the occlusion. The second patient who had
received two SESs died suddenly and we have to consider
this as an acute cardiac and possibly thrombotic event.
Therefore, it seems wise to propose that patients receiv-
ing more than one SES for the treatment of ISR,
particularly in the setting of failed brachytherapy, total
vessel occlusion, or poorly deployed stents, should receive
clopidogrel for an extended period.
Table 5. Individual 9-Month Outcome in 16 Patients Treated With Sirolimus Eluting Stent for ISR
Case
ISR
Pattern
Number of
Previous PCI
Brachytherapy
Failure
Length of
SES (mm)
30-Day
Events
4-Month
Events
4-Month
Restenosis
9-Month
Events*
1 Diffuse 4 Yes 18 No Death — Death
2 Total occlusion 1 No 18 No No No No
3 Focal 3 No 36 No No No Death
4 Total occlusion 1 No 90 No No No Q-MI
5 Focal 2 No 18 No No No No
6 Focal 2 Yes 18 No No No No
7 Proliferative 1 No 36 No No No No
8 Proliferative 1 No 18 No No No No
9 Diffuse 1 No 18 No No No No
10 Proliferative 1 No 18 No No No No
11 Diffuse 1 No 18 No No No No
12 Diffuse 2 Yes 18 No No No No
13 Diffuse 2 No 36 No No In-lesion† No
14 Proliferative 1 No 36 No No No No
15 Total occlusion 2 Yes 36 No No In-stent† No
16 Proliferative 2 No 36 No No In-lesion† No
*Events are death, myocardial infarction (MI), target vessel revascularization (percutaneous transluminal coronary angioplasty/coronary artery bypass graft surgery). †No repeat
percutaneous coronary intervention (PCI) was performed. Treatment strategies for restenotic vessels are explained in the Results section.
ISR  in-stent restenosis; SES  sirolimus eluting stent.
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Study limitations. This is a small observational study and
only lesions with vessel diameter between 2.5 to 3.5 mm
were enrolled. Therefore, the results need to be confirmed
by randomized and multicenter trials. Additionally, the
study comprises four months angiographic and IVUS
follow-up. However, the recently reported long-term data,
which demonstrated that the four months results are pre-
served at one year in de-novo lesions, support the notion
that our four months data may be predictive of the long-
term findings (13).
Conclusions. Sirolimus eluting stent implantation is an
effective treatment for patients with complex ISR, even
when they are at an intrinsically high risk for complications.
As the use of drug-eluting stents increases, their complexity
and the range of indications will expand towards higher risk
patient populations. In this setting, stenting the whole area
injured by the balloon, overlapping SESs properly, and good
stent deployment with low residual stenosis, as well as an
appropriate anti-platelet regimen will be the keys to suc-
cessful treatment. When more than one eluting stent is used
to treat long in-stent restenotic lesions, IVUS guidance may
be advisable to optimize complete coverage of previously
implanted bare metal stents and to ensure that the edges of
implanted stents are overlapped.
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